Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy, such as pentostatin, cyclophosphamide, and CAMPATH-1H work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well pentostatin, cyclophosphamide, rituximab, and CAMPATH-1H work in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

Key facts

Study ID

NCT00074282

Run by

Eastern Cooperative Oncology Group

People needed

102

Starts

2005-04-14

Expected to finish

2018-05-06

Last updated by the study team

2023-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of B-cell chronic lymphocytic leukemia (CLL) meeting the following criteria:
• Peripheral blood absolute lymphocyte count greater than 5,000/mm\^3
• Lymphocytosis must comprise small to moderate size lymphocytes with no greater than 55% prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically
• Phenotypically characterized CLL defined by the following:
• Predominant population of cells share B-cell antigens with CD5 in the absence of other pan-T-cell markers (CD3 or CD2)
• B cell expresses either kappa or lambda light chains
• Surface immunoglobulin with low cell surface density expression
• Requires chemotherapy, as indicated by any of the following:
• Disease-related symptoms
• Weight loss of 10% or more within the past 6 months
• Extreme fatigue
• Fevers greater than 100.5°F for 2 weeks without evidence of infection
• Night sweats without evidence of infection
• Evidence of progressive marrow failure manifested by the development of or worsening anemia (hemoglobin no greater than 10 g/dL) and/or thrombocytopenia (platelet count no greater than 100,000/mm\^3)
• Massive (i.e., greater than 6 cm below left costal margin) or progressive splenomegaly
• Massive nodes or clusters (i.e., greater than 10 cm in longest diameter) or progressive adenopathy
• Progressive lymphocytosis with an increase of greater than 50% over a 2-month period OR an anticipated doubling time of less than 6 months
• Demonstrated progression after at least 1 course of either an alkylating agent-based or purine nucleoside-based (e.g., fludarabine) regimen OR failed to achieve a meaningful response OR relapsed after prior therapy
• Patients who have relapsed after a pentostatin-based regimen are eligible provided the response was greater than 12 months prior to study entry
• 18 and over
• ECOG Performance Status 0-2
• Bilirubin no greater than 2 mg/dL (unless secondary to tumor, hemolysis, or Gilbert syndrome)
• Creatinine no greater than 2.0 mg/dL
• Creatinine clearance ≥ 30 mL/min
• Negative pregnancy test

You may not qualify if…

• Bone marrow dysplasia related to prior therapy
• New York Heart Association class III or IV heart failure
• Prior lenalidomide
• Other malignancy within the past 2 years except squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
• Pregnant or nursing
• Concurrent oral or IV antibiotics for active infection

Where it is running

• Aurora Presbyterian Hospital — Aurora, Colorado, United States
• Boulder Community Hospital — Boulder, Colorado, United States
• Penrose Cancer Center at Penrose Hospital — Colorado Springs, Colorado, United States
• St. Anthony Central Hospital — Denver, Colorado, United States
• Presbyterian - St. Luke's Medical Center — Denver, Colorado, United States
• St. Joseph Hospital — Denver, Colorado, United States
• Rose Medical Center — Denver, Colorado, United States
• CCOP - Colorado Cancer Research Program — Denver, Colorado, United States
• Swedish Medical Center — Englewood, Colorado, United States
• North Colorado Medical Center — Greeley, Colorado, United States
• Littleton Adventist Hospital — Littleton, Colorado, United States
• Sky Ridge Medical Center — Lone Tree, Colorado, United States
• Hope Cancer Care Center at Longmont United Hospital — Longmont, Colorado, United States
• McKee Medical Center — Loveland, Colorado, United States
• St. Mary - Corwin Regional Medical Center — Pueblo, Colorado, United States
• North Suburban Medical Center — Thornton, Colorado, United States
• Exempla Lutheran Medical Center — Wheat Ridge, Colorado, United States
• Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center — Hartford, Connecticut, United States
• Tunnell Cancer Center at Beebe Medical Center — Lewes, Delaware, United States
• CCOP - Christiana Care Health Services — Newark, Delaware, United States
• Baptist Cancer Institute - Jacksonville — Jacksonville, Florida, United States
• Lakeland Regional Cancer Center at Lakeland Regional Medical Center — Lakeland, Florida, United States
• Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center — Boise, Idaho, United States
• Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
• Mayo Clinic Scottsdale — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.